Clinical trial • Phase I • Neurology
NBI-1076986 for Movement disorders
Phase I trial of NBI-1076986 for Movement disorders. None/Not specified-controlled. 130 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Movement disorders
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 11-12-2023
- First CTIS Authorization Date
- 16-02-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 130
Recruitment
- Planned Sample Size
- 130
- Recruitment Window Months
- 35
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 130
Netherlands
- Earliest CTIS Part Ii Submission Date
- 13-02-2024
- Latest Decision Or Authorization Date
- 19-12-2025
- Processing Time Days
- 675
- Number Of Sites
- 1
- Number Of Participants
- 130
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Neurology
- Principal Investigator Name
- P. Kremer
- Principal Investigator Email
- clintrials@chdr.nl
- Contact Person Name
- P. Kremer
- Contact Person Email
- clintrials@chdr.nl
- Number Of Participants
- 130
Sponsor
Primary sponsor
- Full Name
- Neurocrine Biosciences Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- NBI-1076986
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke